Company: HURA
Filing Date: 2025-02-07
Form Type: S-4
Source: 0001193125-25-022803
Chunk: 839

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-02-07
Form: S-4
Chunk 839
---
 |    $ |     |
|                                             |     |  December 31, |      |   |     |      |     |
|                                             |     |          2023 |      |   |     | 2022 |     |
|                                             |     | -in thousands |      |   |     |      |     |
| Balance as of beginning of period           |     |             $ |  442 |   |     |    $ |   — |
| Increase due to acquisition                 |     |               |    — |   |     |      | 442 |
| Decrease for provision of research services |     |               | (442 | ) |     |      |   — |
| Balance as of end of period                 |     |             $ |    — |   |     |    $ | 442 |

Merck In connection with the Merger, the Company became the successor in interest to the Merck Neuromuscular License Agreement with Merck to support research, development and commercialization of products for treatment of neuromuscular diseases, including amyotrophic lateral sclerosis (“ALS”). As of December 31, 2022, the Company had $442,000 in deferred revenue under the Merck Neuromuscular License Agreement. The Company recognized collaboration revenue of $442,000 for the year ended December 31, 2023, due to completion of research and development services provided by us, and zero for the year ended December 31, 2022. As of December 31, 2023, the Company had zero in deferred revenue under the Merck Neuromuscular License Agreement. 13. Stock-Based Compensation 2008 Equity Incentive Plan The Company’s 2008 Equity Incentive Plan (the “2008 Plan”) provided for the grant of incentive stock options, non-statutorystock options, restricted stock awards and restricted stock units to employees and non-employeeservice providers of the Company. Under the 2008 Plan, the exercise price of stock options granted were at 100% of the estimated fair market value of the Company’s common stock on the date of grant and the contractual term of stock options granted were between five and ten years. Options become vested and, if applicable, exercisable based on terms determined by the Company’s board of directors or other plan administrator on the date of grant, which is continued employment or service as defined in each option agreement. In 2018, the 2008 Plan expired and 209,